Literature DB >> 15730113

Community pharmacy Target Intervention Program to improve aspirin use in persons with diabetes.

Stephanie A Haggerty1, Jennifer Cerulli, Mario M Zeolla, Jean S Cottrell, Macary B Weck, John J Faragon.   

Abstract

OBJECTIVE: To identify the rate of aspirin or antiplatelet/anticoagulant use in persons with diabetes presenting to community pharmacies and determine whether a student pharmacist-driven Target Intervention Program (TIP) could increase the number of eligible persons with diabetes receiving aspirin therapy in accordance with American Diabetes Association (ADA) recommendations.
DESIGN: Unblinded, single intervention.
SETTING: Eight Community Pharmacy Advanced Practice Experience (CPAPE) sites in New York State. PARTICIPANTS: Persons having prescriptions filled for diabetes medications or supplies who were not receiving antiplatelet/anticoagulant medications.
INTERVENTIONS: Assessment sheets were completed by student pharmacists for eligible patients to determine appropriateness for aspirin therapy. Recommendations for aspirin therapy were faxed to physicians when indicated, and physicians responded via fax for aspirin therapy implementation. The student pharmacists contacted patients, informed patients of physician decisions, and provided appropriate counseling. MAIN OUTCOME MEASURES: Number of persons with diabetes currently receiving aspirin or antiplatelet/anticoagulant medications and the number initiated on aspirin as a result of the TIP.
RESULTS: A total of 436 persons with diabetes were identified. Of those contacted, 322 agreed to participate and 31 declined; 228 were taking aspirin or other antiplatelet/anticoagulant agents at baseline. Students completed assessment sheets, which were forwarded to physicians, for 79 subjects potentially eligible to receive aspirin therapy; 65 physician responses were received (82% response rate). Aspirin therapy was initiated in 53 patients (67%).
CONCLUSION: The TIP enabled CPAPE students to increase aspirin use among eligible persons with diabetes in accordance with ADA guidelines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15730113     DOI: 10.1331/1544345052843020

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  10 in total

1.  [Finding the right platelet anti-aggregant prescription for type-2 diabetes patients, according to the ADA 2003 criteria].

Authors:  Sandra Raméntol Teys; Vicenta Pujol Blaya; Mónica León de la Fuente; María León-Sanromà
Journal:  Aten Primaria       Date:  2006-10-31       Impact factor: 1.137

2.  Description and Evaluation of an MPharm Practice-based Experience Pilot Program.

Authors:  Philip Winn; Christopher J Turner
Journal:  Am J Pharm Educ       Date:  2016-11-25       Impact factor: 2.047

Review 3.  Pharmacy Student Learning During Advanced Pharmacy Practice Experiences in Relation to the CAPE 2013 Outcomes.

Authors:  Vincent C Dennis; Dianne W May; Tina J Kanmaz; Shannon L Reidt; Michelle L Serres; Heather D Edwards
Journal:  Am J Pharm Educ       Date:  2016-09-25       Impact factor: 2.047

4.  Qualitative Evaluation of a Practice-based Experience Pilot Program for Master of Pharmacy Students in Scotland.

Authors:  Gillian Hendry; Philip Winn; Sally Wiggins; Christopher J Turner
Journal:  Am J Pharm Educ       Date:  2016-12-25       Impact factor: 2.047

5.  Engaging students in wellness and disease prevention services.

Authors:  Audra S Anderson; Jean-Venable R Goode
Journal:  Am J Pharm Educ       Date:  2006-04-15       Impact factor: 2.047

Review 6.  Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.

Authors:  Marc Cohen
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

7.  Women's health promotion within a community advanced pharmacy practice experience.

Authors:  Jennifer Cerulli; Margaret Malone
Journal:  Am J Pharm Educ       Date:  2008-04-15       Impact factor: 2.047

8.  Prevalence of antiplatelet therapy in patients with diabetes.

Authors:  Shaun R Miller; Benjamin Littenberg; Charles D MacLean
Journal:  Cardiovasc Diabetol       Date:  2005-12-01       Impact factor: 9.951

9.  NSAID-avoidance education in community pharmacies for patients at high risk for acute kidney injury, upstate New York, 2011.

Authors:  Soo Min Jang; Jennifer Cerulli; Darren W Grabe; Chester Fox; Joseph A Vassalotti; Alexander J Prokopienko; Amy Barton Pai
Journal:  Prev Chronic Dis       Date:  2014-12-18       Impact factor: 2.830

10.  Retrospective Study of Appropriate Primary Prevention in Postmenopausal Women Presenting with a Major Adverse Cardiovascular Endpoint (MACE).

Authors:  Nicole E Cieri-Hutcherson; Aleksandra Lomakina; Maya R Chilbert
Journal:  Pharmacy (Basel)       Date:  2022-08-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.